Neuroone Medical Technologies is trading 5.11% down now at $1.44 after fiscal third-quarter product revenue missed estimates and management lowered its fiscal 2026 outlook.
- On August 13, 2026, product revenue was $1.97 million versus the $2.5 million analyst estimate.
- Record 59.9% product gross margins and $2.7 million in new orders provided offsets.
- Results were scheduled before market open, followed by an 8:30 a.m. conference call.